Immunocore(IMCR)

Search documents
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Globenewswire· 2025-01-06 12:00
Company Overview - Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX, designed to treat a broad range of diseases including cancer, autoimmune, and infectious diseases [4] - The company leverages its proprietary ImmTAX platform to develop a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease, and multiple earlier pre-clinical programs [4] - Immunocore's most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom [4] Upcoming Event - Immunocore management will participate in a presentation at the 43rd Annual J P Morgan Healthcare Conference in San Francisco, California, scheduled for Wednesday, January 15, 2025, at 8:15 a m Pacific Standard Time (PST) [2][3] - The presentation will be webcast live and accessible via the "Events & Presentations" section under "Investors" on Immunocore's website, with a replay available for a limited time following the event [3]
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Globenewswire· 2024-12-23 12:00
Immunocore's IMC-P115C Phase 1 Trial - Immunocore has dosed the first patient in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate targeting PRAME-expressing tumors [6] - IMC-P115C is designed with the same CD3 effector and TCR specificity as brenetafusp, but with an extended half-life [6] - The Phase 1 trial will evaluate safety, pharmacokinetics, and clinical activity in HLA-A*02:01-positive patients with advanced solid tumors expressing PRAME [6][7] IMC-P115C Development and Mechanism - IMC-P115C is Immunocore's first half-life extended candidate and the sixth ImmTAC candidate to enter clinical trials [2] - It is a PRAME x CD3 ImmTAC bispecific protein targeting the same HLA-A*02:01 PRAME peptide as brenetafusp [2] - The trial aims to assess preliminary anti-tumor activity and pharmacokinetics of IMC-P115C [8] ImmTAC Technology Overview - Immunocore's ImmTAC molecules are bispecific biologics designed to redirect the immune system to recognize and kill cancerous cells [3] - These molecules use engineered soluble TCRs to recognize intracellular cancer antigens with ultra-high affinity and selectively kill cancer cells via an anti-CD3 immune-activating effector function [3] - The ImmTAC mechanism has potential to treat both hematologic and solid tumors, including immune "cold" low mutation rate tumors [3] Immunocore's Pipeline and Focus - Immunocore is a commercial-stage biotechnology company developing TCR bispecific immunotherapies called ImmTAX for cancer, autoimmune diseases, and infectious diseases [4] - The company has a deep pipeline with nine active clinical and pre-clinical programs across multiple therapeutic areas [9] - Its most advanced oncology TCR therapeutic, KIMMTRAK, is approved for unresectable or metastatic uveal melanoma in several regions [9] Clinical Development and Future Prospects - The Phase 1 trial of IMC-P115C builds on the largest Phase 1/2 PRAME dataset from brenetafusp, which served as the basis for the first Phase 3 trial with a PRAME therapy [7] - Immunocore aims to expand the understanding of PRAME candidates through this trial [7] - The company continues to pioneer transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [6]
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Newsfilter· 2024-12-17 12:00
Clinical Trial and Drug Development - Immunocore has initiated a Phase 1/2 trial for IMC-R117C, targeting PIWIL1 in advanced cancers, including colorectal cancer, marking the first immunotherapy program to target this cancer-testis antigen [1][2] - IMC-R117C is the fifth ImmTAC candidate from Immunocore to enter clinical trials, with PIWIL1 being overexpressed in multiple malignancies, including colorectal cancer, and associated with aggressive tumor growth and poor patient survival [2] - The trial will evaluate IMC-R117C as a monotherapy and in combination with standard therapies, focusing on HLA-A*02:01-positive patients with advanced solid tumors [4][6] Market and Patient Population - Immunocore estimates that up to 20,000 colorectal cancer patients globally are positive for both PIWIL1 and HLA-A*02:01, highlighting a significant unmet medical need in this patient population [3] - Colorectal cancer remains one of the most prevalent cancers, with low survival rates for advanced or metastatic cases, despite advancements in treatment [7] Technology and Mechanism of Action - Immunocore's ImmTAC molecules are a novel class of bispecific biologics designed to redirect the immune system to recognize and kill cancerous cells, leveraging ultra-high affinity TCRs to target intracellular cancer antigens [5] - The ImmTAC platform has the potential to treat both hematologic and solid tumors, including immune "cold" tumors with low mutation rates, due to its mechanism of T cell infiltration into tumors [5] Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, with a pipeline that includes nine active clinical and pre-clinical programs across oncology, infectious diseases, and autoimmune diseases [9] - The company's most advanced oncology therapeutic, KIMMTRAK, has been approved for the treatment of uveal melanoma in multiple regions, including the United States and the European Union [9]
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Benzinga· 2024-12-13 19:10
Morgan Stanley Analyst Actions - Morgan Stanley downgraded Amicus Therapeutics Inc FOLD to Equal-weight from Overweight and lowered the price target from $17 to $12 [2] - The analyst noted that Amicus is well-positioned but expectations are largely priced into shares [1] - Investors are shifting focus to the company's next leg of growth, with potential updates to the pipeline in 2025 and beyond [2] Immunocore Holdings plc IMCR Analysis - Morgan Stanley lowered the price target for Immunocore Holdings plc IMCR from $74 to $35 due to disappointing data for brenetafusp in cutaneous melanoma and ovarian cancer [3] - The analyst continues to give full credit for Kimmtrak (tebentafusp), which was approved for unresectable or metastatic uveal melanoma [3] - Limited upside potential is seen from additional brenetafusp updates as the company detects signals in metastatic NSCLC and combination in earlier-line NSCLC [4] Immuneering Corp IMRX Analysis - Morgan Stanley downgraded Immuneering Corp IMRX shares to Underweight from Equal-weight and set a base case range of $1 to $5 versus the previous target of $4 [5] - The analyst supports Immuneering's strategy of targeting the MAPK pathway but notes stronger investment opportunities in the coverage on a relative basis [5] - Early clinical results are promising but more robust data with a larger patient pool is needed to confirm outcomes [6] Stock Price Movements - IMRX stock is down 18% at $1 615 [6] - IMCR stock is down 5 89% at $28 53 [6] - FOLD stock is down 6 70% at $9 47 [6]
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
ZACKS· 2024-12-12 18:06
Zacks Rank Upgrade and Earnings Estimates - Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting an upward trend in earnings estimates, which is a powerful force impacting stock prices [1] - The Zacks rating system relies on changes in a company's earnings picture, tracking EPS estimates for the current and following years through the Zacks Consensus Estimate [2] - The upgrade to a Zacks Rank 1 indicates a positive earnings outlook for Immunocore, which could favorably impact its stock price [3] Earnings Estimate Revisions and Stock Price Movement - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements [4] - Institutional investors use earnings estimates to calculate the fair value of a company's shares, and revisions in these estimates lead to buying or selling, causing stock price movements [4] - Rising earnings estimates and the consequent rating upgrade for Immunocore imply an improvement in the company's underlying business, which investors may reward by pushing the stock higher [5] Zacks Rank System and Historical Performance - The Zacks Rank system classifies stocks into five groups based on four factors related to earnings estimates, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7] - Immunocore's placement in the top 5% of Zacks-covered stocks, with a Zacks Rank 1, indicates superior earnings estimate revisions, making it a strong candidate for market-beating returns [10][11] Immunocore's Earnings Estimate Revisions - Immunocore is expected to earn -$0.94 per share for the fiscal year ending December 2024, representing a year-over-year change of 16.8% [8] - Over the past three months, the Zacks Consensus Estimate for Immunocore has increased by 43.7%, reflecting steady upward revisions by analysts [8] Zacks Rank System's Unique Approach - Unlike Wall Street analysts' rating systems, which tend to be overly optimistic, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings across its universe of over 4,000 stocks [9] - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, and the next 15% receive a 'Buy' rating, making the Zacks Rank system a reliable indicator of superior earnings estimate revisions [9][10]
New Strong Buy Stocks for December 12th
ZACKS· 2024-12-12 12:21
Stocks Added to Zacks Rank 1 (Strong Buy) List - NB Bancorp Inc (NBBK): The bank holding company for Needham Bank has seen an 11% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Omnicell Inc (OMCL): The medication management solutions provider has experienced a 20% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - ZIM Integrated Shipping Services Ltd (ZIM): The container shipping provider has seen a 35.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR): The biotechnology company has experienced a 47.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - UL Solutions Inc (ULS): The safety science services provider has seen a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
GlobeNewswire News Room· 2024-12-03 06:00
KIMMTRAK Reimbursement Agreement - KIMMTRAK (tebentafusp) has been recommended for funding through the NHS in England by NICE for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma [1] - This recommendation overturns the initial negative decision by NICE in May 2023, which the company successfully appealed in December 2023 [2] - KIMMTRAK is now funded on the NHS in England as of 02 December 2024 [4] Impact on Patients and Medical Community - KIMMTRAK is the first therapy to improve survival for HLA-A*02:01-positive metastatic or unresectable uveal melanoma, marking a major step forward for patients and their families [3] - Uveal melanoma is a very rare form of melanoma requiring different clinical management, and the option to prescribe tebentafusp represents a significant advancement for patients [3] - The recommendation highlights the power of collaboration between patients, advocates, and medical experts in advancing care for ocular melanoma [4] About KIMMTRAK and Uveal Melanoma - KIMMTRAK is a novel bispecific protein targeting gp100, a lineage antigen expressed in melanocytes and melanoma, developed using Immunocore's ImmTAC technology platform [6] - Uveal melanoma is a rare and aggressive form of melanoma affecting the eye, with up to 50% of patients developing metastatic disease and historically having no approved treatment until KIMMTRAK [5] - KIMMTRAK is indicated as monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, including the US, EU, Canada, Australia, and the UK [7] Immunocore's Technology and Pipeline - Immunocore's proprietary TCR technology generates ImmTAC molecules, designed to redirect the immune system to recognize and kill cancerous cells, with potential applications in hematologic and solid tumors [9] - The company is a commercial-stage biotechnology firm pioneering the development of TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune diseases, and infectious diseases [10] - Immunocore has nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases, with KIMMTRAK being its most advanced oncology TCR therapeutic [10]
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?
ZACKS· 2024-11-28 16:01
Stock Performance and Price Targets - Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) gained 2 9% over the past four weeks closing at $32 83 with a potential upside of 112 8% based on the mean price target of $69 87 [1] - The mean estimate includes 15 short-term price targets with a standard deviation of $21 22 indicating variability among analysts The lowest estimate is $24 (26 9% decline) while the most optimistic target is $100 (204 6% surge) [2] - A low standard deviation suggests greater agreement among analysts which could be a good starting point for further research [7] Analysts' Price Targets and Earnings Estimates - Analysts' growing optimism over IMCR's earnings prospects is supported by strong agreement in revising EPS estimates higher which historically correlates with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year increased by 44% over the past month with eight positive revisions and no negative revisions [10] - IMCR holds a Zacks Rank 1 (Strong Buy) placing it in the top 5% of over 4 000 stocks based on earnings estimate factors indicating strong potential upside [11] Limitations of Price Targets - Price targets can mislead investors as empirical research shows they rarely predict actual stock price movements accurately [5] - Analysts may set overly optimistic price targets to generate interest in stocks often influenced by business incentives rather than unbiased analysis [6] - Investors should not rely solely on price targets for investment decisions as they should be treated with skepticism [8]
New Strong Buy Stocks for November 26th
ZACKS· 2024-11-26 12:26
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ZIM Integrated Shipping Services Ltd. (ZIM) : This container shipping provider has seen the Zacks Consensus Estimate for its current year earnings increasing 41.7% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days.Rush Street Interactive, Inc. (RSI) : This online casino and sports betting company has ...
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
ZACKS· 2024-11-08 15:55
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $34.31, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.93 indicates an 112.6% upside potential.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $18.74. While the lowest estimate indicates a decline of 30.1% fro ...